

# Fresenius with +100 years of experience, we are committed to life!

We are saving and improving human lives with **affordable, accessible and innovative healthcare products and the highest quality in clinical care.**

## Full Year 2024

Group Revenue<sup>1</sup> (org.)

**€21.5bn** (+8%<sup>2</sup>)

Group EBIT<sup>1</sup> (cc)

**€2.5bn** (+10%<sup>3</sup>)

EPS<sup>1,4</sup> (cc)

**€2.59** (+13%<sup>3</sup>)

Market Capitalization<sup>5</sup>

**€18.9bn**



**FRESENIUS  
KABI**

**€8,414m** (+10%<sup>2</sup>)

**#1 Global provider** for IV Drugs,  
Parental Nutrition, and Blood collection

**#2** Enteral Nutrition Europe and China  
Infusion Systems Europe and LATAM

### Pharma:

Hospital-sold generic IV  
Drugs and Fluids



**Basis**

### Nutrition:

Enteral and Parenteral  
Nutrition products



### MedTech:

Stationary drug delivery  
and therapy devices



### Biopharma:

AIID & oncology biologic  
drugs (biosimilars)



**Growth vectors**

**450m PATIENTS** are in touch with  
our products and services




**FRESENIUS  
HELIOS**

**€12,739m** (+6%)

**#1 Hospital provider in Europe**

- **135 hospitals** across Germany & Spain
- **System-critical** networks
- **Superior medical quality** and best in-class innovation



**26m PATIENTS** are treated  
in our hospitals each year

<sup>1</sup> Before special items | <sup>2</sup> Growth rates adjusted for accounting effects related to Argentina hyperinflation. | <sup>3</sup> Growth rate adjusted for Argentina hyperinflation | <sup>4</sup> Excluding Fresenius Medical Care | <sup>5</sup> Total number of ordinary shares multiplied by the respective Xetra year-end quotation on the Frankfurt Stock Exchange



**Healthcare is in change...  
...we are part  
of the solution!**

**Aging global  
population**

**Growing technological  
progress**

**Rising chronic  
diseases**

**Increasing  
healthcare spend**


## Uniquely positioned – Fresenius meets evolving patients’ needs with a broad portfolio across three therapy platforms

### Covering the entire patient journey

- **Health equity:** Providing affordable and accessible products and services
- **Integrated therapy:** Driving multimodal therapies across three platforms
- **Digital solutions & AI:** Enhancing clinical outcomes, quality and, productivity
- **Human touch:** From cutting-edge technology to human-to-human care

### Taking performance to the next level

- **Simpler, stronger and more focused:** #FutureFresenius clearly paying off, meaningful organic growth and shareholder value
- **Long term delivery:** Strong financial results through ambitious, transparent financial framework
- **Accelerating performance:** Excellent EPS growth and ambitious leverage target ratio



	<b>FRESENIUS KABI</b>	<b>FRESENIUS HELIOS</b>
EBIT MARGIN	<b>16–18%</b> <span style="background-color: #0070C0; color: white; border-radius: 50%; padding: 2px;">NEW</span> Previously: 14–17%	<b>10–12%</b>
ORGANIC REVENUE GROWTH	<b>4–7%</b>	<b>4–6%</b>
CAPITAL EFFICIENCY <b>ROIC</b>	<b>6–8%</b>	CAPITAL STRUCTURE <b>Leverage ratio</b> Previously: 3.0–3.5x
	<span style="background-color: #0070C0; color: white; border-radius: 50%; padding: 2px;">NEW</span>	CASH CCR <sup>1</sup> <b>~1</b>
	<span style="background-color: #0070C0; color: white; border-radius: 50%; padding: 2px;">NEW</span>	<b>FY/24 DIVIDEND<sup>3</sup>: €1.00</b>
	<b>DIVIDEND POLICY</b> <b>Pay out 30-40% of core net income<sup>2</sup></b>	

<sup>1</sup> Cash conversion rate – defined as adjusted FCFBIT / EBIT (before special items) | <sup>2</sup> Before special items; excl. FMC | <sup>3</sup> Dividend proposal to AGM on May 23, 2025; All figures before special items